TRVI
vs
S&P 500
TRVI
S&P 500
Over the past 12 months, TRVI has significantly outperformed S&P 500, delivering a return of +159% compared to the S&P 500's +12% growth.
Stocks Performance
TRVI vs S&P 500
Performance Gap
TRVI vs S&P 500
Performance By Year
TRVI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Trevi Therapeutics Inc
Glance View
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 24 full-time employees. The company went IPO on 2019-05-07. The firm is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The company is also developing Haduvio in levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. The company is conducting a Phase 2b/3 clinical trial of Haduvio in patients with severe pruritus associated with prurigo nodularis. The company is also conducting a Phase 2 clinical trial of Haduvio for chronic cough in patients with IPF. The company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus, Pruritus in Chronic Liver Disease and Uremic Pruritus Programs.
